Labcorp Announces Cash Dividend of $0.72 per Share for Stockholders

Labcorp Announces Quarterly Cash Dividend

Burlington, N.C., April 10, 2025 – Labcorp Holdings Inc. (NYSE: LH), a globally recognized leader in laboratory services, has made a significant announcement regarding its financial returns to shareholders. The company's Board of Directors has approved a cash dividend of $0.72 per share for its common stock.

The dividend is scheduled to be payable on June 11, 2025, to stockholders who are on record as of the close of business on May 29, 2025. This decision reflects Labcorp’s ongoing commitment to supporting its investors while continuing its trajectory of innovation and growth in laboratory services.

About Labcorp

Founded with the mission of improving health and enhancing lives through innovative laboratory services, Labcorp operates with nearly 70,000 employees and spans across 100 countries. The company provides diagnostics and drug development laboratory capabilities that empower doctors, hospitals, pharmaceutical companies, researchers, and patients to make informed and confident healthcare decisions. Approximately 75% of new drugs and therapeutic solutions approved by the FDA in 2024 received support through Labcorp’s service offerings, which further underscores the vital role the company plays in the healthcare landscape.

Financial Stability and Growth

Labcorp’s decision to increase its dividend illustrates a robust financial performance in recent times. The company has consistently prioritized returning value to its shareholders, which is reflected in its dividend history. The declared dividend not only represents a reward for investors but also denotes the company’s strength and stable earnings amidst a competitive market.

With its advanced diagnostic capabilities, Labcorp continues to be at the forefront of innovations that improve patient care. The company’s investments in technology and research further solidify its position as a leader in the laboratory services sector.

Recent Developments

Looking ahead, Labcorp is also set to announce its first-quarter financial results on April 29, 2025. Investors and analysts will closely watch these results as they provide insight into the company’s performance and its response to evolving market demands. Additionally, Labcorp recently announced its acquisition of specific assets from BioReference Health, which enhances its oncology and clinical testing services, emphasizing its continual expansion in vital healthcare service areas.

Conclusion

Labcorp’s proactive approach in managing dividends reflects positively on its operational capabilities and financial health. With a commitment to providing unparalleled diagnostic services and further investments aimed at innovation, Labcorp is poised for continued success in the healthcare industry. As stockholders await the next dividend payment, the anticipation grows for what the company will divulge in its upcoming financial report. This moment marks not only an important milestone for shareholders but also a reinforcement of Labcorp's dedication to maintaining leadership in laboratory solutions.

For more information about Labcorp and its services, visit www.labcorp.com.